share_log

BioNTech | 6-K: Report of foreign private issuer (related to financial reporting)

BioNTech | 6-K: Report of foreign private issuer (related to financial reporting)

BioNTech | 6-K：外國發行人報告（業績相關）
美股SEC公告 ·  2024/08/05 18:37

Moomoo AI 已提取核心訊息

BioNTech reported Q2 2024 revenues of €128.7 million, down from €167.7 million year-over-year, with a net loss of €807.8 million. The company invested €525.6 million in R&D during Q2, with approximately 90% focused on non-COVID-19 activities, primarily oncology. The financial position remains strong with €18.5 billion in cash and investments as of June 30, 2024.The company achieved significant clinical milestones, including positive data from multiple mRNA cancer vaccine trials. Notably, the Phase 2 trial of BNT111 met its primary efficacy endpoint in melanoma patients. BioNTech also launched its updated variant-adapted COVID-19 vaccine in the EU and received UK approval, while initiating a rolling sBLA with the U.S. FDA.BioNTech reiterated its 2024 revenue guidance of €2.5-3.1 billion, expecting the majority of revenues in Q4. The company continues to advance its oncology pipeline with multiple clinical trials, including combinations of novel therapeutics, while expanding manufacturing capabilities through strategic partnerships like the €145 million CEPI collaboration for vaccine production in Rwanda.
BioNTech reported Q2 2024 revenues of €128.7 million, down from €167.7 million year-over-year, with a net loss of €807.8 million. The company invested €525.6 million in R&D during Q2, with approximately 90% focused on non-COVID-19 activities, primarily oncology. The financial position remains strong with €18.5 billion in cash and investments as of June 30, 2024.The company achieved significant clinical milestones, including positive data from multiple mRNA cancer vaccine trials. Notably, the Phase 2 trial of BNT111 met its primary efficacy endpoint in melanoma patients. BioNTech also launched its updated variant-adapted COVID-19 vaccine in the EU and received UK approval, while initiating a rolling sBLA with the U.S. FDA.BioNTech reiterated its 2024 revenue guidance of €2.5-3.1 billion, expecting the majority of revenues in Q4. The company continues to advance its oncology pipeline with multiple clinical trials, including combinations of novel therapeutics, while expanding manufacturing capabilities through strategic partnerships like the €145 million CEPI collaboration for vaccine production in Rwanda.
BioNTech報告2024年第二季度營業收入爲12870萬歐元，同比下降16770萬歐元，淨損失爲80780萬歐元。該公司在第二季度投資了52560萬歐元用於研發，其中約90%集中在非COVID-19活動，主要是腫瘤學。截至2024年6月30日，公司的財務狀況仍然強勁，現金和投資總額爲185億歐元。該公司實現了重要的臨牀里程碑，包括多項mRNA癌症生物-疫苗試驗的積極數據。值得注意的是，BNT111的第二階段試驗在黑色素瘤患者中達到了主要有效性終點。BioNTech還在歐盟推出了更新版適應變種的COVID-19生物-疫苗，並獲得了英國的批准，同時啓動了與美國FDA的滾動生物-疫苗申請。BioNTech重申其2024年營業收入指導爲25-31億歐元，預計大部分收入將在第四季度實現。該公司繼續推進其腫瘤學產品線，進行多項臨牀試驗，包括新型治療的組合，同時通過與CEPI的14500萬歐元合作擴展其製造能力，以在盧旺達進行生物-疫苗生產。
BioNTech報告2024年第二季度營業收入爲12870萬歐元，同比下降16770萬歐元，淨損失爲80780萬歐元。該公司在第二季度投資了52560萬歐元用於研發，其中約90%集中在非COVID-19活動，主要是腫瘤學。截至2024年6月30日，公司的財務狀況仍然強勁，現金和投資總額爲185億歐元。該公司實現了重要的臨牀里程碑，包括多項mRNA癌症生物-疫苗試驗的積極數據。值得注意的是，BNT111的第二階段試驗在黑色素瘤患者中達到了主要有效性終點。BioNTech還在歐盟推出了更新版適應變種的COVID-19生物-疫苗，並獲得了英國的批准，同時啓動了與美國FDA的滾動生物-疫苗申請。BioNTech重申其2024年營業收入指導爲25-31億歐元，預計大部分收入將在第四季度實現。該公司繼續推進其腫瘤學產品線，進行多項臨牀試驗，包括新型治療的組合，同時通過與CEPI的14500萬歐元合作擴展其製造能力，以在盧旺達進行生物-疫苗生產。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    美聯儲暫停降息，你如何調整持倉？
    美聯儲宣布基準利率維持在4.25%—4.50%不變，符合市場預期。你會如何配置資產？ 展开
    FOMC新聞發佈會，2025年1月29日